Loberg, Matthew A.
Bell, Rebecca K.
Goodwin, Leslie O.
Eudy, Elizabeth
Miles, Linde A.
SanMiguel, Jennifer M.
Young, Kira
Bergstrom, David E.
Levine, Ross L.
Schneider, Rebekka K.
Trowbridge, Jennifer J. http://orcid.org/0000-0002-7636-9504
Article History
Received: 11 October 2018
Revised: 27 November 2018
Accepted: 13 December 2018
First Online: 28 January 2019
Compliance with ethical standards
:
: R.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis. He receives research support from and consulted for Celgene and Roche, research support from Prelude Therapeutics, and has consulted for Novartis and Gilead. He has received honoraria from Lilly and Amgen for invited lectures. The remaining authors declare that they have no conflict of interest.